The history and future of targeting cyclin-dependent kinases in cancer therapy
Open accessThe DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Abstract
Cancer represents a pathological manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies. In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle. Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events. Translating this knowledge into successful clinical development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clinical trials. Here, we review the biology of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clinical results of CDK inhibitors. We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clinical activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Grade 3–4 neutropenia is observed in approximately 60% of patients taking palbociclib and ribociclib (Asghar et al., 2015; Hortobagyi et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like palbociclib, these orally-bioavailable and highly selective CDK4/6-targeting agents exhibit IC50 values in the low nanomolar range, whereas other CDK family members are far less sensitive (1, 88, 89).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Such pan-CDK inhibitors had limited success, due in part to the dose limiting toxicities that hampered their use (Asghar et al., 2015).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“More than two decades after discovery of CDK4 and CDK6, drugs inhibiting their activities are now demonstrating significant efficacy in cancer treatment [for other recent reviews, see (1-3)].”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
In the citing paper
“Abemaciclib appears to be better tolerated overall, with only 55% of patients experiencing significant adverse events (as compared to 70–80% with ribociclib and palbociclib) and only 21% with grade 3–4 neutropenia.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
Cited by
Items 601–700 of 1,002
Yang, Y., Cui, H., & Wang, X. (2018) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2018.1553604 · Cited by 32
“mation, and chromosome segregation [26].”
Omar, H. A., & Tolba, M. F. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.01.009 · Cited by 32
Psoriatic epidermis is associated with upregulation of CDK 2 and inhibition of CDK 4 activity
Henri, P., Prével, C., Pellerano, M., Lacotte, J., Stoebner, P., Morris, M. C., & Meunier, L. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18178 · Cited by 32
Xu, J., Huang, F., Yao, Z., Jia, C., Xiong, Z., Liang, H., Lin, N., & Deng, M. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0398-3 · Cited by 32
Yeh, I., Esakov, E. L., Lathia, J. D., Miyagi, M., Reizes, O., & Montano, M. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-54184-0 · Cited by 32
Integrating proteomics into precision oncology
Wahjudi, L. W., Bernhardt, S., Abnaof, K., Horak, P., Kreutzfeldt, S., Heining, C., Borgoni, S., Becki, C., Berg, D., Richter, D., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33301 · Cited by 32
“It must be noted that success of current targeted therapies in the basket cell cycle regulation (eg, using the CDK4/6 inhibitor palbociclib) depends on the expression of wildtype RB1 protein.(51) Although proteomics can quantify the level of total and of phosphorylated RB1, protein and phosphoprotein data cannot refle…”
BackgroundPujol, J.-L., Vansteenkiste, J., Rodríguez, L. P.-A., Gregorc, V., Mazières, J., Awad, M. M., Janne, P. A., Chisamore, M. J., Hossain, A. M., Chen, Y., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100234 · Cited by 32
“Inhibiting CDK 4 and 6 may prevent cell cycle progression, thus arresting tumor growth.(1,2) In addition to cell cycle deregulation, cancer cells have the ability to escape immune surveillance.”
BackgroundXu, F., Tong, M., Tong, C. S. W., Chan, B. K. C., Chu, H. Y., Wong, T. L., Fong, J. H. C., Cheung, M. S. H., Mak, K. H.-M., Pardeshi, L. A., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1017 · Cited by 32
Recent Developments of Flavonoids with Various Activities
Sun, Z.-G., Li, Z.-N., Zhang, J.-M., Hou, X.-Y., Yeh, S. M., & Ming, X. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220117111858 · Cited by 32
Carpintero-Fernández, P., Borghesan, M., Eleftheriadou, O., Pan‐Castillo, B., Fafián‐Labora, J., Mitchell, T. P., Yuste, A., Öğrünç, M., Nightingale, T. D., Mayán, M. D., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04569-3 · Cited by 32
Li, R., Li, H., Lan, J., Yang, D., Lin, X., Xu, H., Han, B., Yang, M., Su, B., Liu, F., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154084 · Cited by 32
Azaindole derivatives as potential kinase inhibitors and their SARs elucidation
Fang, G., Chen, H., Cheng, Z., Tang, Z., & Wan, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115621 · Cited by 32
Zhang, Y.-Z., Chen, X., Fan, X., He, J., Huang, J., Xiao, D., Zhou, Y., Zheng, S., Xu, J., Yao, X., et al. (2016) · Molecules · doi:10.3390/molecules21030374 · Cited by 32
“In eukaryotic cells, cell cycle evolved an integrated protective mechanism, which regulated by a group of cyclin, cyclin-dependent kinases (CDK), and CKIs [56–58].”
BackgroundYao, G., Tang, J. P., Yang, X., Zhao, Y., Zhou, R., Meng, R., Zhang, S., Dong, X., Zhang, T., Yang, K., et al. (2020) · Theranostics · doi:10.7150/thno.42578 · Cited by 32
Li, L., Miao, W., Huang, M., Williams, P. B., & Wang, Y. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.000957 · Cited by 31
Ji, X., Wei, X., Qian, J., Mo, X., Kai, G., An, F., & Lü, Y. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.05.041 · Cited by 31
Liu, Q., Liu, S., Wang, X., Zhang, J., & Liu, K. (2019) · Infectious Agents and Cancer · doi:10.1186/s13027-019-0238-5 · Cited by 31
Robert, T., Johnson, J. L., Guichaoua, R., Yaron, T. M., Bach, S., Cantley, L. C., & Colas, P. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00147 · Cited by 31
Gao, X., Jiang, Y., Xu, Q., Liu, F., Pang, X., Wang, M., Li, Q., & Li, Z. (2021) · Foods · doi:10.3390/foods10092036 · Cited by 31
“Cell cycle activities are usually regulated by cyclins (CCNs), cycle-dependent kinases (CDKs), and cyclin-dependent kinase inhibitors (CKIs) to maintain the activities of normal cell [12].”
BackgroundCDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
Salvador-Barberó, B., Álvarez‐Fernández, M., Zapatero‐Solana, E., Bakkali, A. E., Menéndez, M. D. C., Lopez-Casas, P. P., Domenico, T. D., Xie, T., VanArsdale, T. L., Shields, D. J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.012 · Cited by 31
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31
“been shown to be closely related to tumorigenesis and tumor development, making them important targets for the treatment of cancer (Asghar et al., 2015; Malumbres, 2014).”
BackgroundA patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022)
Kovalová, M., Baraka, J. P., Mik, V., Jorda, R., Luo, L., Shao, H., & Kryštof, V. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2195547 · Cited by 31
“The other group of more than 200 potent CDK7 inhibitors structurally based on 1,2,3,4-tetrahydro-2,6-naphthyridine or 5,6,7,8-tetrahydropyrido[3,4-d ]pyrimidine, including for example 65 , was disclosed by Janssen Pharmaceutica [123].”
InfluentialSawant, M., Wilson, A., Sridaran, D., Mahajan, K. N., O’Conor, C. J., Hagemann, I. S., Luo, J. R., Weimholt, C., Li, T., Roa, J. C., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02747-x · Cited by 31
“The CDK inhibitors inhibit the downstream CDK4/6-mediated phosphorylation of Rb, which although potently arrest cell cycle, requires functional Rb protein [47].”
BackgroundSmall molecule agents for triple negative breast cancer: Current status and future prospects
Ou, Y., Wang, M., Xu, Q., Sun, B., & Jia, Y. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101893 · Cited by 31
“Targeting CDK4/6 can block the cell cycle, inhibit tumor cell proliferation and division, and promote their apoptosis [91].”
BackgroundTargeting protein kinases to reverse multidrug resistance in sarcoma
Chen, H., Shen, J. K., Choy, E., Hornicek, F. J., & Duan, Z. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.011 · Cited by 31
Bahleda, R., Grilley‐Olson, J. E., Govindan, R., Barlési, F., Greillier, L., Pérol, M., Ray-Coquard, I. L., Strumberg, D., Schultheis, B. S., Dy, G. K., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.92 · Cited by 31
“Through overexpression or amplification of cell-cycle activators (e.g., D- or E-type cyclins, CDK4, CDK6) and by inactivation of cell-cycle inhibitors, CDKs contribute to deregulation of the cell cycle in tumour cells (Lapenna and Giordano, 2009; Asghar et al, 2015).”
BackgroundKujan, O., Huang, G., Ravindran, A., Vijayan, M., & Farah, C. S. (2019) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12903 · Cited by 31
Stojakovic, A., Chang, S.-Y., Nesbitt, J., Pichurin, N. P., Ostroot, M. A., Aikawa, T., Kanekiyo, T., & Trushina, E. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-201015 · Cited by 32
Zacksenhaus, E., Liu, J.-K., Jiang, Z., Yao, Y., Xia, L., Shrestha, M., & Ben‐David, Y. (2016) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2016.10.003 · Cited by 30
Rondla, R., Padmarao, L. S., Ramatenki, V., Abdelmonsef, A. H., Potlapally, S. R., & Vuruputuri, U. (2017) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2017.11.005 · Cited by 31
Drug repositioning using drug-disease vectors based on an integrated network
Lee, T., & Yoon, Y. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2490-x · Cited by 30
Shi, D., Zhao, P., Cui, L., Li, H., Sun, L. L., Niu, J., & Chen, M. (2020) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-020-00410-9 · Cited by 30
Systematic Identification of Molecular Targets and Pathways Related to Human Organ Level Toxicity
Xu, T., Wu, L., Xia, M., Simeonov, A. M., & Huang, R. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00305 · Cited by 30
Liao, Y., Wu, N., Wang, K., Wang, M., Wang, Y., Gao, J., Zhong, B., Ma, F., Wu, Y., & Jiang, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.617758 · Cited by 30
“Cyclins could function as the regulators of CDK kinases (Hu et al., 2014; Asghar et al., 2015).”
BackgroundFadaka, A. O., Sibuyi, N. R. S., Bakare, O. O., Klein, A., Madiehe, A. M., & Meyer, M. (2021) · Biotechnology Reports · doi:10.1016/j.btre.2021.e00602 · Cited by 30
Wang, C., Li, H., Wu, L., Jiao, X., Jin, Z., Zhu, Y., Fang, Z., Zhang, X., Huang, H., & Zhao, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668743 · Cited by 30
“Therefore, looking for specific inhibitors that regulate CDK4, developing highly selective drugs for CDK4, and preparing reasonable and effective combined strategies for specific patients are of great significance for improving the clinical treatment effect of CRC patients (38).”
BackgroundA patent review of anticancer CDK2 inhibitors (2017–present)
Said, M. A., Abdelrahman, M. A., Abourehab, M. A. S., Farès, M., & Eldehna, W. M. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2078193 · Cited by 30
“The Cyclin–CDK complex is subsequently activated via phosphorylation by CDK-activating kinase (CAK) [1].”
BackgroundInfluentialLooking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer
Rubinstein, M. M. Z., Shen, S., Monk, B. J., Tan, D. S. P., Nogueira‐Rodrigues, A., Aoki, D., Sehouli, J., & Makker, V. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.10.012 · Cited by 30
Tokarski, R. J., Sharpe, C., Huntsman, A. C., Mize, B. K., Ayinde, O. R., Stahl, E. H., Lerma, J. R., Reed, A., Carmichael, B., Muthusamy, N., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115342 · Cited by 30
Song, X., Chen, F., Dai, Y., Sun, Y., Qiu, C., Lin, X., & Xu, R. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02589-8 · Cited by 30
“Preclinical studies revealed that CDK7 inhibitors caused cell cycle arrest, apoptosis and suppression of transcription, encouraging researchers to explore potent CDK7 inhibitors for breast cancer therapies [13 – 18].”
Inhibitors and PROTACs of CDK2: challenges and opportunities
Zeng, Y., Ren, X., Jin, P., Fan, Z., Liu, M., Zhang, Y., Li, L., Zhuo, M., Wang, J., Li, Z., et al. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2376655 · Cited by 30
“The monomeric form of CDK2 is inactive and becomes active upon forming a functional heterodimeric complex with one of its two regulatory partners, cyclins A or E [6].”
Paradoxical roles of cyclin D1 in DNA stability
Jirawatnotai, S., & Sittithumcharee, G. (2016) · DNA repair · doi:10.1016/j.dnarep.2016.04.011 · Cited by 30
Knudsen, E. S., & Witkiewicz, A. K. (2016) · Oncotarget · doi:10.18632/oncotarget.11588 · Cited by 32
“The canonical function of CDK4/6 inhibition is to elicit the functional activation of the RB tumor suppressor and block subsequent cell cycle progression [22, 23].”
BackgroundSelf-citationZhang, X., Zhuang, R., Ye, Q., Zhuo, J., Chen, K., Lu, D., Wei, X., Xie, H., Xu, X., & Zheng, S. (2019) · Journal of Cancer · doi:10.7150/jca.28317 · Cited by 30
“In normal cells, the Cdk1/cyclin B1 complex remains inactive until the end of G2 phases a result of inhibitory phosphorylation of CDK1[21, 22].”
BackgroundDiscovery of CDK5 Inhibitors through Structure-Guided Approach
Khair, N. Z., Lenjisa, J. L., Tadesse, S., Kumarasiri, M., Basnet, S. K. C., Mekonnen, L. B., Li, M., Diab, S., Sykes, M. J., Albrecht, H., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00029 · Cited by 30
Chagaleti, B. K., Saravanan, V., & Kathiravan, M. K. (2024) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-024-00577-8 · Cited by 29
Transcriptional modules related to hepatocellular carcinoma survival: coexpression network analysis
Xu, X., Zhou, Y., Miao, R., Chen, W., Qu, K., Pang, Q., & Liu, C. (2016) · Frontiers of Medicine · doi:10.1007/s11684-016-0440-4 · Cited by 29
Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition
Schedin, T., Borges, V. F., & Shagisultanova, E. I. (2018) · International Journal of Breast Cancer · doi:10.1155/2018/7835095 · Cited by 29
“CDK2 inhibitors might provide the ability to target tumors driven by cyclin E1 amplification [45, 102].”
BackgroundAnti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Wang, S., Zhou, D., Xu, Z., Song, J., Qian, X., Lv, X., & Luan, J. (2019) · Current Drug Targets · doi:10.2174/1389450120666190402145325 · Cited by 29
Gagliato, D. D. M., Buzaid, A. C., Pérez-García, J. M., Llombart‐Cussac, A., & Cortés, J. (2020) · Cancers · doi:10.3390/cancers12092480 · Cited by 29
“In turn, cyclin D can activate both CDK4 and CDK6, which through phosphorylation of RB1, and release of transcription factor E2F, and promote cell cycle progression from the mitosis phase G1 to S, resulting in DNA replication [2,3].”
BackgroundMcAnulty, J., & DiFeo, A. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249486 · Cited by 30
“These trials included patients of many cancer types and were not selective to MYC-amplified patients [90].”
BackgroundMerritt, J. M., Borkar, I. V., Buser, J. Y., Brewer, A. C., Campos, O., Fleming, J. A., Hansen, C., Humenik, A., Jeffery, S. P., Kokitkar, P. B., et al. (2021) · Organic Process Research & Development · doi:10.1021/acs.oprd.1c00198 · Cited by 29
Khaleghi, S., Khayatzadeh, J., & Neamati, A. (2022) · Materials Technology · doi:10.1080/10667857.2022.2044218 · Cited by 29
“Targeting the cyclin-dependent kinases has been successfully applied in suppressing and regulating the cancer cell cycle events as an efficient cancer therapy strategy [6,7].”
MethodHajjo, R., Sabbah, D. A., Abusara, O. H., Kharmah, R., & Bardaweel, S. K. (2023) · Viruses · doi:10.3390/v15020568 · Cited by 29
“Hence, several pharmacological CDKis have been developed and tested clinically for the potential use as cancer therapeutic options [78,79], with only three selective pharmacological CDKis on CDK4/6, namely palbociclib, ribociclib, and abemaciclib, being approved for the treatment of metastatic breast cancer along with…”
BackgroundCDK3, target of miR-4469, suppresses breast cancer metastasis via inhibiting Wnt/β-catenin pathway
Cao, T., Xiao, T., Huang, G., Xu, Y., Zhu, J. J., Wang, K., Ye, W., Guan, H., He, J., & Zheng, D. (2017) · Oncotarget · doi:10.18632/oncotarget.18171 · Cited by 29
Ghorab, M. M., Ragab, F. A.-F., Heiba, H. I., Elsayed, M., & Ghorab, W. M. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.06.010 · Cited by 29
An TRIM 59‐ CDK 6 axis regulates growth and metastasis of lung cancer
Geng, B., Liang, M., Qin, L., Zhao, W., wang, H., Wang, L., Pan, X., & Chen, X. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14052 · Cited by 29
“It is widely accepted that CDK6 is a leading gene relating to tumour growth and metastasis.(11) Therefore, further investigation of the above association of TRIM59 and CDK6 is of pivotal importance.”
BackgroundCdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors
Carter, A. M., Kumar, N., Herring, B., Tan, C., Guenter, R. E., Telange, R., Howse, W., Viol, F., McCaw, T. R., Bickerton, H. H., et al. (2021) · Oncogenesis · doi:10.1038/s41389-021-00372-5 · Cited by 30
Overexpressed DEPDC1B contributes to the progression of hepatocellular carcinoma by CDK1
Dang, X., Pan, Q., Lin, Z.-H., Wang, H., Li, L.-H., Li, L., Shen, D., & Wang, P.-J. (2021) · Aging · doi:10.18632/aging.203016 · Cited by 28
“CDK1 can cooperate with cyclins A and B to promote S, G2, and M phase progression, CHK1 and WEE1 can inhibit CDK1 through inhibitory phosphorylation and CDC25 family [12, 30, 31], therefore the down-regulated CDK1 and CCNB coordinated to lead G2/M phase in the study.”
BackgroundHuang, J., Wang, X., Dong, R., Liu, X., Li, H., Zhang, T., Xu, J., Liu, C., Zhang, Y., Hou, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00271 · Cited by 28
Synthetic approaches for BF2-containing adducts of outstanding biological potential. A review
Delgado, D., & Abonía, R. (2021) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.103528 · Cited by 28
New Advances in Targeted Therapy of HER2-Negative Breast Cancer
An, J., Peng, C. Y., Xie, X., & Peng, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.828438 · Cited by 29
“ATP-competitive CDK inhibitors play an inhibitory effect by mimicking the ATP structure and binding to CDK protein (96),”
Background‘Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics’
Mehmood, S., Faheem, M. Q., Ismail, H., Farhat, S. M., Ali, M., Younis, S., & Asghar, M. N. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.783494 · Cited by 28
Qayed, W. S., Hassan, M. A., El-Sayed, W. M., Silva, J. R. A., & Aboul‐Fadl, T. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105884 · Cited by 28
Yang, A.-Y., Liu, H., & Yang, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1072547 · Cited by 28
“CDK1 is a typical cell cycle checkpoint involved in cell proliferation and transcription regulation (Asghar et al., 2015); it is essential for cell cycle progression to M phase, which is related to cyclin A and B, respectively, and regulates the transformation of S-G2 and G2-M.”
BackgroundAdvances in synthesis and biological evaluation of CDK2 inhibitors for cancer therapy
Patel, D. A., Patel, S. S., & Patel, H. D. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107045 · Cited by 28
Zhou, Z., Lei, J., Fang, J., Chen, P., Zhou, J., Wang, H., Sun, Z., Chen, Y., & Yin, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112637 · Cited by 28
Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222
Dommer, A. P., Kumarasamy, V. M., Wang, J., O’Connor, T. N., Roti, M., Mahan, S., McLean, K., Knudsen, E. S., & Witkiewicz, A. K. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2244 · Cited by 28
Self-citationCritical reanalysis of the methods that discriminate the activity of CDK2 from CDK1
Sakurikar, N., & Eastman, A. R. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1160983 · Cited by 28
CDKL1 promotes tumor proliferation and invasion in colorectal cancer
Qin, C., Ren, L., Ji, M., Lv, S., Wei, Y., Zhu, D., Lin, Q., Xu, P., Chang, W., & Xu, J. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s133014 · Cited by 29
“Moreover, P57/Kip2 as an inhibitor of several cyclin–CDK complexes has been proven to be a tumor suppressor,(13) and a variety of medications targeting CDKs have undergone clinical trials for gastrointestinal cancer, breast cancer, and leukemia.(14,15) As a mimic of CDKs, whether CDKL1 is involved in the progression o…”
Prp19 Arrests Cell Cycle via Cdc5L in Hepatocellular Carcinoma Cells
Huang, R., Xue, R., Qu, D., Yin, J., & Shen, X. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040778 · Cited by 28
“Therefore, targeting the mitotic stage of the cell cycle may be an effective approach for cancer therapy [5].”
BackgroundCDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer
Pan, Q., Sathe, A., Black, P. C., Goebell, P. J., Kamat, A. M., Schmitz‐Dräger, B. J., & Nawroth, R. (2017) · Bladder Cancer · doi:10.3233/blc-170105 · Cited by 28
“However, first generation inhibitors such as flavopiridol are non-selective and can inhibit multiple CDKs which might result in limited efficacy and high toxicity [8].”
BackgroundFascaplysin inhibit ovarian cancer cell proliferation and metastasis through inhibiting CDK4
Chen, S., Guan, X., Wang, L., Li, B., Sang, X., Liu, Y. Z., & Zhao, Y. (2017) · Gene · doi:10.1016/j.gene.2017.09.009 · Cited by 28
Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer
Luca, A. D., Maiello, M. R., D’Alessio, A., Frezzetti, D., Gallo, M., Carotenuto, M., & Normanno, N. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1514720 · Cited by 29
“Palbociclib and ribociclib induce myelosuppression, and are generally dosed with a one-week break to recover neutrophil counts in patients, whereas abemaciclib is dosed continuously and elicits fatigue and diarrhea as more relevant dose-limiting toxicities [9].”
BackgroundSabzichi, M., Ramezani, M., Mohammadian, J., Ghorbani, M., Mardomi, A., Najafipour, F., & Mehdizadeh, A. (2019) · Process Biochemistry · doi:10.1016/j.procbio.2019.03.007 · Cited by 28
Deota, S., Rathnachalam, S., Namrata, K., Boob, M. M., Fulzele, A., Radhika, S., Ganguli, S., Balaji, C., Kaypee, S., Vishwakarma, K. K., et al. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.04.005 · Cited by 28
Chen, T., Liu, L., Zou, Y., Hu, X., Zhang, W., Zhou, T., Luo, X., Fu, W., & Xu, J. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0186 · Cited by 28
“Abnormal CCND-CDK4/6-INK4-RB signaling has been involved in tumorigenesis and in tumors 17-21 , and represents a valid therapeutic target 16 .”
CDK9 inhibitors reactivate p53 by downregulating iASPP
Wu, J., Liang, Y., Tan, Y., Tang, Y., Song, H., Wang, Z., Li, Y., & Lu, M. M. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109508 · Cited by 28
The transcription factor MEF2C restrains microglial overactivation by inhibiting kinase CDK2
Hu, X., Wu, J., Shi, L., Wang, F., He, K., Tan, P., Hu, Y., Yang, Y., Wang, D., Ma, T., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.02.026 · Cited by 27
Arvejeh, P. M., Chermahini, F. A., Marincola, F. M., Taheri, F., Mirzaei, S. A., Alizadeh, A., Deris, F., Jafari, R., Amiri, N., Soltani, A. K., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06396-4 · Cited by 28
Zhou, Y., Zhang, N., Chen, W., Zhao, L., & Zhong, R. (2016) · Physical Chemistry Chemical Physics · doi:10.1039/c5cp06276d · Cited by 27
Bouclier, C., Simon, M., Laconde, G., Pellerano, M., Diot, S., Lantuéjoul, S., Busser, B., Vanwonterghem, L., Vollaire, J., Josserand, V., et al. (2020) · Theranostics · doi:10.7150/thno.40971 · Cited by 27
“throughput screening assays, or through structure-guided approaches [9-13].”
BackgroundChen, X., Shu, C., Li, W., Hou, Q., Luo, G., Yang, K., & Wu, X. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00063 · Cited by 27
Bai, S., Taylor, S. E., Jamalruddin, M. A., McGonigal, S. C., Grimley, E. C., Yang, D., Bernstein, K. A., & Buckanovich, R. J. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0873 · Cited by 27
CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer
Zeng, S., Lan, B., Ren, X., Zhang, S., Schreyer, D., Eckstein, M., Yang, H., Britzen‐Laurent, N., Dahl, A., Mukhopadhyay, D., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02443-w · Cited by 27
“DNA replication and CDK1 activity are mediated by checkpoint signaling kinases such as CHK1 and WEE1, which suppress the activity of CDK1 via inhibitory phosphorylation [57].”
BackgroundExploiting pivotal mechanisms behind the senescence-like cell cycle arrest in cancer
Zarneshan, S. N., Fakhri, S., Bachtel, G., & Bishayee, A. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.11.007 · Cited by 27
Alanazi, A. S., Mirgany, T. O., Alsfouk, A. A., Alsaif, N. A., & Alanazi, M. M. (2023) · Medicina · doi:10.3390/medicina59030610 · Cited by 27
Antonarelli, G., Salimbeni, B. T., Marra, A., Espósito, A., Locatelli, M., Trapani, D., Pescia, C., Fusco, N., Curigliano, G., & Criscitiello, C. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104148 · Cited by 27
The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Gomes, I., Abreu, C., Costa, L., & Casimiro, S. (2023) · Cancers · doi:10.3390/cancers15194835 · Cited by 27
“The first-generation (e.g., flavopiridol, roscovitine) and second-generation (e.g., dinaci-clib, SNS-032) CDKi were potent nonspecific pan-CDKi that ultimately failed to demonstrate efficacy in clinical trials, with a low therapeutic index and high-toxicity profiles [20,22].”
Gomha, S. M., Zaki, M. E. A., Maliwal, D., Pissurlenkar, R. R. S., Ibrahim, M., Fathalla, M., & Hussein, A. M. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.101209 · Cited by 27
She, Y., Guo, Z., Zhai, Q., Liu, J., Du, Q., & Zhang, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1378090 · Cited by 27
Hamed, O. A., El‐Sayed, N. A., Mahmoud, W. R., & Elmasry, G. F. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107413 · Cited by 27
Emerging targeted therapies for melanoma
Johnson, D. B., Pollack, M. L. H., & Sosman, J. A. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1184644 · Cited by 27
“most solid tumors.[48,49] By contrast, these agents appear to produce additive benefits in combination with other therapies in both breast cancer [50]and melanoma.”
BackgroundYeganeh, S. M., Vasei, M., Tavakoli, R., Kia, V., & Paryan, M. (2016) · European Journal of Cancer Care · doi:10.1111/ecc.12496 · Cited by 27
Elevated E2F7 expression predicts poor prognosis in human patients with gliomas
Yin, W., Wang, B., Ding, M., Huo, Y., Hu, H., Cai, R., Zhou, T., Gao, Z., Wang, Z., & Chen, D. (2016) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2016.04.019 · Cited by 27
Lin, X., Tian, L., Wang, L., Li, W., Xu, Q., & Xiao, X. (2017) · Oncology Letters · doi:10.3892/ol.2017.5614 · Cited by 27
“Cyclins and CDKs are overexpressed and dysregulated in a variety of types of human cancer and p21 and p27 are frequently mutated and exhibit reduced expression levels (33).”
Welch, D. B. M., Jauch, A. S., Langowski, J., Olins, A. L., & Olins, D. E. (2017) · Nucleus · doi:10.1080/19491034.2017.1285989 · Cited by 27
High-content analysis screening for cell cycle regulators using arrayed synthetic crRNA libraries
Strezoska, Ž., Perkett, M. R., Chou, E. T., Maksimova, E. M., Anderson, E. M., McClelland, S., Kelley, M. L., Vermeulen, A., & Smith, A. V. B. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.017 · Cited by 27
“The primary screen identified many expected modulators of mitotic progression (PLK1, AURKA, AURKB, CDC20, CDT1, CDK1, CDC27, CDC6…) (Asghar et al., 2015; Goldenson and Crispino, 2015; Okayama, 2012; Vaid et al., 2016).”
Akkol, E. K., Bardakçı, H., Barak, T. H., Aschner, M., Karatoprak, G. Ş., Khan, H. Z., & Hussain, Y. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/6044640 · Cited by 27
“It has been revealed that various tumorigenic incidents drive proliferation by a ff ecting the complexes of CDK4 or CDK6 in the G1 or S phase or and G2/M control regulated by CDK1 and CDK2 [45, 46].”
Metal‐Containing Pharmacophores in Molecularly Targeted Anticancer Therapies and Diagnostics
Yang, M., & Bierbach, U. (2016) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201601149 · Cited by 26
Metadata
- Authors
- Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S.
- Affiliations
- Institute of Cancer Research (GB)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Royal Marsden NHS Foundation Trust (GB)
- Corresponding author
- Knudsen, Erik S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-01-30
- Volume
- 14
- Issue
- 2
- Pages
- 130-146
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4480421
- OpenAlex
- W2057272791
- Cited by
- 1,767
- References
- 210
- Citations by year
- 2026: 100 · 2025: 157 · 2024: 157 · 2023: 170 · 2022: 180 · 2021: 200 · 2020: 185 · 2019: 148 · 2018: 150 · 2017: 161 · 2016: 112 · 2015: 46
- FWCI
- 27.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Consortium canadien en neurodégénérescence associée au vieillissement
- Cancer Research UK (16642)
- National Cancer Institute (R01CA129134, CA129134, CA188650, R01CA188650, CA163863, R01CA163863)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin-dependent kinases, cyclin-dependent kinase inhibitors, CDK4, CDK6, CDK2, CDK1, cell cycle regulation, G1 phase, chromosome stability, S phase, anticancer drug development, clinical trials, patient stratification, kinase selectivity
- MeSH terms
- Animals, Antineoplastic Agents, Cell Cycle, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Molecular Structure, Signal Transduction, Gene Expression Regulation, Neoplastic, Cyclin-Dependent Kinases, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.